Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT02632708
Title Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Agios Pharmaceuticals, Inc.
Age Groups: adult | senior
Covered Countries USA | DEU

Facility Status City State Zip Country Details
City of Hope Duarte California 91010 United States Details
UCLA Medical Center Los Angeles California 90024 United States Details
University of Colorado Aurora Colorado 80045 United States Details
University of Chicago Chicago Illinois 60637 United States Details
Johns Hopkins University Baltimore Maryland 21231 United States Details
Dana Farber Cancer Institute Boston Massachusetts 02114 United States Details
Massachusetts General Hospital Boston Massachusetts 02114 United States Details
Hackensack University Medical Center Hackensack New Jersey 07601 United States Details
Memorial Sloan Kettering Cancer Center New York New York 10021 United States Details
Ohio State University Columbus Ohio 43210 United States Details
Medical University of South Carolina - PPDS Charleston South Carolina 29425-0001 United States Details
Vanderbilt University Medical Center Nashville Tennessee 37232 United States Details
University of Texas Southwestern Medical Center Dallas Texas 75390 United States Details
MD Anderson Cancer Center Houston Texas 77030 United States Details
Universitatsklinikum Ulm Ulm 89081 Germany Details
VU Medisch Centrum Amsterdam 1081 HV Netherlands Details
Erasmus MC Rotterdam 3075 EA Netherlands Details
*Shaded cells indicate that there was no data available from for the field